National Cancer Institute; Notice of Closed Meetings, 69119 [E9-30923]

Download as PDF Federal Register / Vol. 74, No. 249 / Wednesday, December 30, 2009 / Notices mstockstill on DSKH9S0YB1PROD with NOTICES amended (5 U.S.C. Appendix 2) notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal NCI committees that will decide whether NCI should support requests and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel, NCI Experimental Therapeutics Program (NExT) Cycle 2. Date: January 13, 2010. Time: 8:30 a.m.–4:30 p.m. Agenda: To evaluate the NCI Experimental Therapeutics Program Portfolio. Place: National Institutes of Health, Building 31A—Conference Room 8A28, 31 Center Drive, Bethesda, MD 20817. Contact Person: Dr. Barbara Mroczkowski, Executive Secretary, NCI Experimental Therapeutics Program, National Cancer Institute, NIH, 31 Center Drive, Room 3A44, Bethesda, MD 20892. (301) 496–4291. mroczkowskib@mail.nih.gov. This notice is being published less than 30 days prior to the meeting due to scheduling conflicts. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: December 22, 2009. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–31012 Filed 12–29–09; 8:45 am] BILLING CODE 4140–01–P VerDate Nov<24>2008 19:01 Dec 29, 2009 Jkt 220001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel, NCI Discovery and Development P01. Date: February 2–3, 2010. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814. Contact Person: Sergei Radaev, PhD., Scientific Review Officer, Resources And Training Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8113, Rockville, MD 20852, 301–435–5655, sradaev@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel, Epidemiology, Prevention, Control & Population Sciences. Date: February 9–11, 2010. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda North Marriott Hotel & Conference Center, Montgomery County Conference Center Facility, 5701 Marinelli Road, North Bethesda, MD 20852. Contact Person: Wlodek Lopaczynski, M.D., PhD, Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8131, Bethesda, MD 20892, 301–594–1402, lopacw@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel, Molecular Oncology—Basic, Translational, and Clinical Studies. Date: February 9–11, 2010. Time: 5 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD. Contact Person: David G. Ransom, PhD, Scientific Review Officer, Research Programs PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 69119 Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Blvd., Rm. 8133, Bethesda, MD 20892–8328, 301–451–4757, david.ransom@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel, SPORE in Gynecologic, Breast, and Skin Cancers. Date: February 17–19, 2010. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, Bethesda, MD. Contact Person: Caron A. Lyman, PhD, Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd, Room 8119, Bethesda, MD 20892–8328, 301–451–4761, lymanc@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel, SPORE in Brain, Leukemia, Myeloma, Sarcoma, Esophageal, GI, HN, and Pancreatic Cancers. Date: February 17–19, 2010. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Shamala K. Srinivas, PhD., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 8123, Bethesda, MD 20892, 301–594–1224, ss537t@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: December 21, 2009. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–30923 Filed 12–29–09; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2009–N–0664] Advisory Committees; Tentative Schedule of Meetings for 2010 AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is announcing a tentative schedule of forthcoming meetings of its public advisory E:\FR\FM\30DEN1.SGM 30DEN1

Agencies

[Federal Register Volume 74, Number 249 (Wednesday, December 30, 2009)]
[Notices]
[Page 69119]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-30923]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel, NCI Discovery and Development P01.
    Date: February 2-3, 2010.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 
20814.
    Contact Person: Sergei Radaev, PhD., Scientific Review Officer, 
Resources And Training Review Branch, Division of Extramural 
Activities, National Cancer Institute, 6116 Executive Blvd., Room 
8113, Rockville, MD 20852, 301-435-5655, sradaev@mail.nih.gov.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel, Epidemiology, Prevention, Control & Population Sciences.
    Date: February 9-11, 2010.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Bethesda North Marriott Hotel & Conference Center, 
Montgomery County Conference Center Facility, 5701 Marinelli Road, 
North Bethesda, MD 20852.
    Contact Person: Wlodek Lopaczynski, M.D., PhD, Scientific Review 
Officer, Research Programs Review Branch, Division of Extramural 
Activities, National Cancer Institute, 6116 Executive Blvd., Room 
8131, Bethesda, MD 20892, 301-594-1402, lopacw@mail.nih.gov.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel, Molecular Oncology--Basic, Translational, and Clinical 
Studies.
    Date: February 9-11, 2010.
    Time: 5 p.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Bethesda North Marriott Hotel & Conference Center, 5701 
Marinelli Road, Bethesda, MD.
    Contact Person: David G. Ransom, PhD, Scientific Review Officer, 
Research Programs Review Branch, Division of Extramural Activities, 
National Cancer Institute, NIH, 6116 Executive Blvd., Rm. 8133, 
Bethesda, MD 20892-8328, 301-451-4757, david.ransom@nih.gov.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel, SPORE in Gynecologic, Breast, and Skin Cancers.
    Date: February 17-19, 2010.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hyatt Regency Bethesda, Bethesda, MD.
    Contact Person: Caron A. Lyman, PhD, Scientific Review Officer, 
Research Programs Review Branch, Division of Extramural Activities, 
National Cancer Institute, 6116 Executive Blvd, Room 8119, Bethesda, 
MD 20892-8328, 301-451-4761, lymanc@mail.nih.gov.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel, SPORE in Brain, Leukemia, Myeloma, Sarcoma, Esophageal, GI, 
HN, and Pancreatic Cancers.
    Date: February 17-19, 2010.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 
Wisconsin Avenue, Bethesda, MD 20814.
    Contact Person: Shamala K. Srinivas, PhD., Scientific Review 
Officer, Research Programs Review Branch, Division of Extramural 
Activities, National Cancer Institute, 6116 Executive Boulevard, 
Room 8123, Bethesda, MD 20892, 301-594-1224, ss537t@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: December 21, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-30923 Filed 12-29-09; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.